Market Overview

Merck, GE Healthcare Announce Collaboration on Use of Imaging Biomarkers for Investigational BACE Inhibitor Program

Related MRK
Markets Little Changed Ahead Of The Federal Reserve's Policy Decision
Earnings Expectations For The Week Of July 28: Exxon, Pfizer, Twitter And Much More
Week Ahead: July Jobs Report, FOMC and GDP (Fox Business)
Related GE
Industrial Stock Earnings Fail to Impress These ETFs - ETF News And Commentary
5 Big Companies Seriously Investing In 3D Printing
Most IPOs Since Dot-Com Bubble (Fox Business)

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and GE Healthcare today announced a clinical study collaboration, license and supply agreement for use of [^18F]Flutemetamol, an investigational positron emission tomography (PET) imaging agent, to support Merck's development of MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD).

Accumulation of beta amyloid in the brain is a pathological characteristic related to Alzheimer's disease. Currently, AD is diagnosed by clinical examination (i.e., medical history, physical, neurological, psychiatric and neuropsychological exams, laboratory tests and Magnetic Resonance Imaging [MRI] or Computed Tomography [CT] scan). An AD diagnosis can only be confirmed through histopathological identification of characteristic features, including beta amyloid plaques, in post-mortem brain samples.

Posted-In: News

 

Most Popular

Related Articles (GE + MRK)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters